

IN THE CLAIMS

Insert new claims 43-46 as follows:

43 (New). A method for inhibiting neuronal degeneration caused or exacerbated by glutamate toxicity in the central nervous system (CNS) of an individual in need thereof, comprising causing activated T cells, which have been activated by Cop 1 or a Cop 1-related peptide or polypeptide, to accumulate at the site of neuronal degeneration in the individual in need, thereby inhibiting neuronal degeneration at that site, with the proviso that the individual in need is other than one who has multiple sclerosis.

44 (New). A method in accordance with claim 43, wherein said neuronal degeneration caused or exacerbated by glutamate toxicity is that which is a result of an injury or disease.

45 (New). A method in accordance with claim 43, wherein said activated T cells are caused to accumulate at said site by administering to the individual in need an effective amount of activated T cells which have been activated by Cop 1 or a Cop 1-related peptide or polypeptide.

46 (New). A method in accordance with claim 43, wherein said activated T cells are caused to accumulate at said site by administering to the individual in need an effective amount of Cop 1 or a Cop-1 related peptide or

a<sup>1</sup>  
cont. polypeptide *in vivo*, thereby causing T cells to become activated by said peptide or polypeptide, which T cells will then accumulate at said site.

Amend 2, 4, 8-11, 21-25 and 27 as follows:

a<sup>2</sup> 2 (Amended). A method in accordance with claim 43, wherein the individual in need thereof is being treated post-operatively after tumor removal from or surgery on the CNS to protect CNS cells from glutamate toxicity.

a<sup>3</sup> 4 (Amended). A method in accordance with claim 45, wherein said activated T cells are autologous T cells, or allogeneic T cells from related donors, or HLA-matched or partially matched, semi-allogeneic or fully allogeneic donors.

8 (Amended). A method in accordance with claim 46, wherein said Cop 1 or a Cop 1-related peptide or polypeptide is Cop 1.

a<sup>4</sup>  
sub-B5 9 (Amended). A method in accordance with claim 46, wherein said Cop 1 or a Cop 1-related peptide or polypeptide is a Cop 1-related peptide or polypeptide.

10 (Amended). A method in accordance with claim 46, in which said Cop 1 or a Cop 1-related peptide or polypeptide is administered in a manner which promotes active immunization of the individual so as to build up a critical T cell response.

Q4  
Cond.  
Pat BS

11 (Amended). A method in accordance with claim 46, wherein said Cop 1-related peptide or polypeptide is a random copolymer that cross-reacts functionally with myelin basic protein (MBP) and is capable of competing with MBP on the MHC class II molecule in antigen presentation.

21 (Amended). A method in accordance with claim 44, in which said injury or disease comprises spinal cord injury, blunt trauma, penetrating trauma, hemorrhagic stroke, or ischemic stroke.

Q5

22 (Amended). A method in accordance with claim 44, in which said injury or disease is Diabetic neuropathy, senile dementia, Alzheimer's disease, Parkinson's Disease, facial nerve (Bell's) palsy, glaucoma, Huntington's chorea, amyotrophic lateral sclerosis, status epilepticus, non-arteritic optic neuropathy, or vitamin deficiency.

23 (Amended). A method in accordance with claim 44, in which said injury or disease is epilepsy, amnesia, anxiety, hyperalgesia, psychosis, seizures, oxidative stress, or opiate tolerance and dependence.

24 (Amended). A method in accordance with claim 44, in which said injury or disease is associated with abnormally elevated intraocular pressure.